HEIDELBERGER IONENSTRAHL THERAPIE (HIT) BETRIEBS GESELLSCHAFT AM UNIVERSITATSKLINIKUM HEIDELBERG MIT BESCHRANKTER HAFTUNG

Their core work

HIT operates the Heidelberg Ion-Beam Therapy Center, one of Europe's few clinical facilities delivering heavy ion beam cancer treatment. Embedded within Heidelberg University Hospital, they combine clinical cancer therapy with research into advanced accelerator technologies, beam delivery systems, and radiobiology. Their work bridges medical physics and particle accelerator engineering — they treat patients while simultaneously advancing the underlying technology for next-generation ion therapy systems, including superconducting components.

What they specialise in

How they've shifted over time

In their earlier H2020 participation (2017), HIT engaged in broad accelerator infrastructure research (ARIES) and clinical radiomics (PREDICT), reflecting their dual identity as both a treatment center and a physics research facility. By 2021, their focus sharpened toward heavy ion therapy specifically — HITRIplus and I.FAST both center on next-generation accelerator components like superconducting gantries and synchrotrons, signaling a move from general participation toward deeper specialization in the technology stack that powers ion beam therapy.

HIT is deepening its investment in superconducting accelerator technology for medical applications, positioning itself as a key contributor to the next generation of compact, efficient ion therapy systems.

How they like to work

HIT never leads projects — they consistently join as a participant, partner, or third party, contributing specialized infrastructure and clinical expertise to large research consortia. With 90 unique partners across 19 countries from just 4 projects, they operate within very large European networks (typical of research infrastructure projects). This profile suggests they are a valued specialist contributor that consortia seek out for their unique ion beam facility and clinical data, rather than an organization that builds its own project proposals.

Despite only 4 projects, HIT has collaborated with 90 unique partners across 19 countries, reflecting participation in major pan-European research infrastructure consortia. Their network is heavily weighted toward the European accelerator and medical physics community.

What sets them apart

HIT is one of only a handful of operational heavy ion therapy centers in Europe, making them an irreplaceable partner for any consortium needing access to clinical ion beam infrastructure and real patient treatment data. Their position within Heidelberg University Hospital means they can bridge clinical oncology with fundamental accelerator physics — a combination very few organizations can offer. For consortium builders in medical physics or advanced radiotherapy, HIT provides something that cannot be replicated by simulation alone: a working treatment facility.

Highlights from their portfolio

• HITRIplus
  Directly focused on integrating heavy ion therapy research across Europe, covering everything from biophysics to superconducting gantry development — the most aligned project with HIT's core mission.
• ARIES
  A flagship accelerator research infrastructure project with HIT's largest single funding (€105,250), connecting them to the broader European accelerator community beyond medical applications.
• PREDICT
  Shows HIT's clinical side — contributing radiotherapy data to a personalized medicine project focused on radiomics as a diagnostic decision tool.